Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model

ABSTRACT We evaluated the impact of high (9.5 log10 CFU/g) and moderate (5.5 log10 CFU/g) inocula of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) on the activities of nafcillin, linezolid, vancomycin, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model with simulated endocardial vegetations over 72 h. Human therapeutic dosing regimens for nafcillin, daptomycin, vancomycin, linezolid, and gentamicin were simulated. At a moderate inoculum, nafcillin (MSSA only), vancomycin, and daptomycin demonstrated equivalent and significant (P < 0.01) bactericidal (99.9% kill) activities (decreases of 3.34 ± 1.1, 3.28 ± 0.4, and 3.34 ± 0.8 log10 CFU/g, respectively). Bactericidal activity was demonstrated at 4 h for nafcillin and daptomycin and at 32 h for vancomycin. Linezolid demonstrated bacteriostatic activity over the course of the study period. At a high inoculum, daptomycin exhibited bactericidal activity against both MSSA and MRSA by 24 h (decrease of 5.51 to 6.31 ± 0.10 log10 CFU/g). Nafcillin (versus MSSA), vancomycin, and linezolid (MSSA and MRSA) did not achieve bactericidal activity throughout the 72-h experiment. The addition of gentamicin increased the rate of 99.9% kill to 8 h for daptomycin (P < 0.01) and 48 h for nafcillin (MSSA only) (P = 0.01). The addition of gentamicin did not improve the activity of vancomycin or linezolid for either isolate for the 72-h period. Overall, high-inoculum Staphylococcus aureus had a significant impact on the activities of nafcillin and vancomycin. In contrast, daptomycin was affected minimally and linezolid was not affected by inoculum.

[1]  L. Sabath,et al.  Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Rybak,et al.  Bactericidal Activities of Daptomycin, Quinupristin-Dalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2003, Antimicrobial Agents and Chemotherapy.

[3]  Antina Barger,et al.  Pharmacological indices in antibiotic therapy. , 2003, The Journal of antimicrobial chemotherapy.

[4]  Julie A. Wu,et al.  Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces , 2003, Antimicrobial Agents and Chemotherapy.

[5]  D. Nicolau,et al.  Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. , 2003, The Journal of antimicrobial chemotherapy.

[6]  M. Rybak,et al.  Prediction Model to Identify Patients With Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance , 2003, Infection Control &#x0026; Hospital Epidemiology.

[7]  Fu-Yu Chiang,et al.  Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[8]  D. Ledoux,et al.  Occurrence of MRSA Endocarditis During Linezolid Treatment , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[9]  G. O’Toole,et al.  Alpha-Toxin Is Required for Biofilm Formation by Staphylococcus aureus , 2003, Journal of bacteriology.

[10]  P. Stewart,et al.  Role of Nutrient Limitation and Stationary-Phase Existence in Klebsiella pneumoniae Biofilm Resistance to Ampicillin and Ciprofloxacin , 2003, Antimicrobial Agents and Chemotherapy.

[11]  L. B. Hovde,et al.  Comparison of Linezolid Activities under Aerobic and Anaerobic Conditions against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus faecium , 2003, Antimicrobial Agents and Chemotherapy.

[12]  E. Batard,et al.  In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model , 2002, Antimicrobial Agents and Chemotherapy.

[13]  Debra A. Goff,et al.  Clinical Failures of Linezolid and Implications for the Clinical Microbiology Laboratory , 2002, Emerging infectious diseases.

[14]  W. Craig,et al.  In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid) , 2002, Antimicrobial Agents and Chemotherapy.

[15]  C. Tuazon,et al.  Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Rybak,et al.  In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model , 2002, Antimicrobial Agents and Chemotherapy.

[17]  H. Rohde,et al.  Evaluation of different detection methods of biofilm formation in Staphylococcus aureus , 2002, Medical Microbiology and Immunology.

[18]  A. Tunkel,et al.  Treatment of bacterial meningitis , 2002, Current infectious disease reports.

[19]  Vance G Fowler,et al.  Changing patient characteristics and the effect on mortality in endocarditis. , 2002, Archives of internal medicine.

[20]  R. Wise,et al.  Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. , 2001, The Journal of antimicrobial chemotherapy.

[21]  J. K. Gibson,et al.  Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.

[22]  Steven D. Brown,et al.  In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers , 2001, Antimicrobial Agents and Chemotherapy.

[23]  R. Wise,et al.  Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses , 2001, Antimicrobial Agents and Chemotherapy.

[24]  Michael H. Miller,et al.  Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection , 2001, Antimicrobial Agents and Chemotherapy.

[25]  R. Akins,et al.  Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V , 2001, Antimicrobial Agents and Chemotherapy.

[26]  R. Akins,et al.  In Vitro Activities of Daptomycin, Arbekacin, Vancomycin, and Gentamicin Alone and/or in Combination against Glycopeptide Intermediate-Resistant Staphylococcus aureus in an Infection Model , 2000, Antimicrobial Agents and Chemotherapy.

[27]  G. Kaatz,et al.  Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations , 2000, Antimicrobial Agents and Chemotherapy.

[28]  G. Drusano,et al.  Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[29]  R. Hershow,et al.  Retrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis , 1997, Pharmacotherapy.

[30]  G. Eliopoulos,et al.  Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae , 1997, Antimicrobial agents and chemotherapy.

[31]  J. Rotschafer,et al.  The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. , 1996, The Journal of antimicrobial chemotherapy.

[32]  A. Bisno,et al.  Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. , 1995, JAMA.

[33]  M. Levison,et al.  Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. , 1995, The Journal of antimicrobial chemotherapy.

[34]  A. Widmer,et al.  In vivo verification of in vitro model of antibiotic treatment of device-related infection , 1995, Antimicrobial agents and chemotherapy.

[35]  C. A. Wood,et al.  Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus , 1994, Antimicrobial Agents and Chemotherapy.

[36]  M. Goetz,et al.  Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. , 1993, The Journal of antimicrobial chemotherapy.

[37]  D. Stevens,et al.  Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. , 1993, The Journal of infectious diseases.

[38]  G. Kaatz,et al.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin , 1992, Antimicrobial Agents and Chemotherapy.

[39]  B. R. Reddy,et al.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. , 1991, Annals of internal medicine.

[40]  A. Karchmer Staphylococcus aureus and vancomycin: the sequel. , 1991, Annals of internal medicine.

[41]  W. Peetermans,et al.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection , 1990, Antimicrobial Agents and Chemotherapy.

[42]  P. Small,et al.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users , 1990, Antimicrobial Agents and Chemotherapy.

[43]  M. Rybak,et al.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside. , 1990, The Journal of antimicrobial chemotherapy.

[44]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[45]  R. T. Miller,et al.  Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. , 1988, Annals of internal medicine.

[46]  V. Winn,et al.  The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. , 1988, The Journal of infectious diseases.

[47]  P. Davey,et al.  The inoculum effect with gram-negative bacteria in vitro and in vivo. , 1987, The Journal of antimicrobial chemotherapy.

[48]  P. Coudron,et al.  In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis. , 1987, The Journal of antimicrobial chemotherapy.

[49]  M. Wale,et al.  The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. , 1987, The Journal of antimicrobial chemotherapy.

[50]  R. Eng,et al.  Inoculum effect of beta-lactam antibiotics on Enterobacteriaceae , 1985, Antimicrobial Agents and Chemotherapy.

[51]  M. Sande,et al.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus , 1984, Antimicrobial Agents and Chemotherapy.

[52]  M. Sande,et al.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. , 1982, Annals of internal medicine.

[53]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[54]  H. Eagle,et al.  "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. , 1953, The New England journal of medicine.

[55]  Daptomycin (Cubicin) for skin and soft tissue infections. , 2004, The Medical letter on drugs and therapeutics.

[56]  E. Mylonakis,et al.  Infective endocarditis in adults. , 2001, The New England journal of medicine.

[57]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[58]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[59]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[60]  C. Cherubin,et al.  Inoculum Effect of 3-Lactam Antibiotics on Enterobacteriaceae , 2022 .